In 2020, the HIV Prevention Trials Network announced results from Give PrEP a shot, a global randomized study that compares the effectiveness of injections and oral tablets as pre-exposure prophylaxis (PrEP) to prevent HIV. The study examines whether an experimental treatment based on the injection every 8 weeks of the anti-HIV drug cabotegravir can safely protect people from getting HIV infection at least as well a standard-of-care treatment based on a daily oral tablet of another anti-HIV medication commonly known as Truvada.

Overall, the study included 4,494 eligible participants, with two-thirds (2/3) of the participants being under 30 years of age. The table below reports the number of HIV infections among the study participants for each treatment.